共查询到17条相似文献,搜索用时 234 毫秒
1.
2.
3.
目的:分析
131I治疗Graves甲亢患者的甲状腺功能的变化特点及其治疗前抗体水平与临床疗效的关系。
方法:前瞻性分析2016年3月至5月于中国医科大学附属第一医院首次行
131I治疗的80例Graves甲亢患者的临床资料,其中男性20例、女性60例,年龄19~70 (40.5±12... 相似文献
4.
^131 I治疗儿童Graves‘甲亢安全,有效 总被引:4,自引:0,他引:4
康增寿 《国外医学(放射医学核医学分册)》2001,25(4):149-152
评价了儿童Graves‘甲亢三种治疗方法(抗甲状腺药物,外科手术,^131 I)的利弊,强调用^131 I治疗儿童Graves‘甲亢安全、有效。 相似文献
5.
6.
目的 通过测定Graves甲亢患者131I治疗前后血清促甲状腺激素受体抗体(TRAb)水平的动态变化,探讨TRAb在131I治疗Graves甲亢中的临床价值.方法 回顾性分析我院2008年至2010年12月收治的经131I治疗的Graves甲亢患者,其中有3~18个月完整随访资料者128例,与45名健康对照者分别于13... 相似文献
7.
目的 分析131I治疗后Graves甲状腺功能亢进症(甲亢)疗效与Graves眼病转归的相关关系,探讨131I治疗对Graves眼病转归的影响.方法 652例Graves甲亢合并Graves眼病的患者,均按照常规程序一次性给予治疗量的131I.服用131I前测量患者眼球突出度,并详细记录眼部症状和特征.治疗结束后定期随... 相似文献
8.
9.
10.
11.
Despite extensive use of iodine-131 ((131)I) treatment for Graves' hyperthyroidism, the optimal regimen of pretreatment with antithyroid drugs is still a matter of discussion. Our aim was to evaluate the success of (131)I treatment in patients with Graves' disease without and with pretreatment with methimazole (MMI). In a prospective randomized study 156 patients with Graves' disease were treated with fixed activity of 550 MBq (131)I. First group of 59 patients received only (131)I. The second group of 50 patients received MMI which was stopped seven days before (131)I. The third group of 47 patients received MMI until (131)I application. Patients were followed clinically and biochemically 1, 3, 6 and 12 months after (131)I treatment. Absorbed dose of (131)I and thyroid volume were measured in each patient. Our result showed that (131)I treatment success after twelve months was equally effective in the first and second group (96.6% and 96%, respectively), while in the third group, success was significantly lower (63.8%). Accordingly, the absorbed dose of (131)I was significantly higher in the first and in second group (144±104 Gy and 164±107 Gy, respectively), and lower in the third group (105±58 Gy). Thyroid volume gradually decreased without any significant difference between the three groups. In conclusion, our study provides evidence that application of (131)I is equally effective in the nonpretreated with MMI group and in the group discontinuing MMI one week before (131)I treatment, and it is more effective in these two groups as compared to the group in which pretreatment with MMI was administered till the day of (131)I application. 相似文献
12.
13.
14.
15.
16.
17.
Esfahani AF Kakhki VR Fallahi B Eftekhari M Beiki D Saghari M Takavar A 《Hellenic journal of nuclear medicine》2005,8(3):158-161
Radioiodine (131I) treatment is often applied for the treatment of Graves' disease (GD). The optimal dose of 131I for Graves' hyperthyroidism is debated. Various techniques suggest either fixed doses or varying doses based on elaborate calculations of the gland size, 131I uptake, and 131I turnover. Fixed dose regimens avoid dose calculations but there is no consensus on the actual dose to be administered. We compared two routinely recommended fixed 131I doses of 185 and 370 MBq for this purpose. Fifty nine patients with GD who had not been previously treated with 131I were randomized in two groups. Group A consisted of 33 patients who were treated with 185 MBq of 131I. Group B consisted of 26 patients who were treated with 370 MBq of 131I. Group A patients were 21% male and 78% female, mean age 38.1+/-14.4, range 15 to 77 y. Group B patients were 27% male and 73% female, mean age 40.7+/-11.7, range 27 to 72 y. All patients were reexamined every six months for two years. The following clinical outcomes were noticed: a) Persistent hyperthyroidism, which was considered as failure to treatment, requiring further 131I treatment. b) Hypothyroidism; requiring life-long replacement treatment. c) Euthyroid state. Euthyroid and hypothyroid states were considered as a response to treatment of hyperthyroidism. In Group A, 10 patients (30.3%) became euthyroid and 6 (18.2%) hypothyroid (an overall response of 48.5%), while 17 (51.5%) remained hyperthyroid by the end of the follow-up period. In Group B, 10 patients (38%) became euthyroid and 13 (50%) hypothyroid, an overall response of 88.5%. Non responders were 3 patients (11.5%). No correlation was noted between the outcome of treatment and age, sex, size of the thyroid gland or thyroid uptake in each Group of patients, while a significant correlation was noted between the disease outcome and the amount of administered 131I (P<0.003). The incidence of hypothyroidism by the end of two years of follow up was less in Group A than in Group B and the incidence of non responders to treatment was lower in Group A. In view of the higher cost of treatment, the longer time elapsing to treatment, the number of office visits by the patients and the higher number of patients with persistent hyperthyroidism in Group A, we conclude that a fixed dose of 131I of 370 MBq is more useful and effective for the treatment of GD as compared to 185 MBq of 131I. 相似文献